Natural Substrates of Dipeptidyl Peptidase IV

  • Ingrid De Meester
  • Christine Durinx
  • Gunther Bal
  • Paul Proost
  • Sofie Struyf
  • Filip Goossens
  • Koen Augustyns
  • Simon Scharpé
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 477)


During the last decade it has become clear that DPP IV may have various substrates in vivo and that the preferred peptide will depend on the localization and physiological circumstances. It is at present impossible to depict a certain chain length as the maximal acceptable substrate size as it turns out that the immediate surrounding and surface accessibility of the NH2-terminal dipeptide are determining the susceptibility for cleavage of a peptide.

From the above, it is clear that the result of dipeptide removal by DPP IV may vary from no effect over activation or change in receptor selectivity to inactivation of the substrate. Therefore, biological interpretation of assays that do not distinguish intact and modified peptides, should be interpreted with caution. Furthermore, collection and conservation of samples for peptide analysis should occur in the cold and if possible in the presence of appropriate protease inhibitors.

Clinical implications of peptide processing by DPP IV include that the therapeutic potential of peptides that are degraded by DPP IV may largely be enhanced by creating DPP IV-resistant, active analogues, and that the most suitable NH2-terminal modification may vary from one peptide to another.

Most exciting are the observations that the in vivo introduction of DPP IV specific inhibitors can enhance the levels of intact endogeneous peptides creating therapeutical perspectives (Hoist et al 1998). Extensive in vivo experiments to reveal whether DPP IV is a powerful and safe pharmaceutical target, are awaited with interest.


Pancreatic Polypeptide Gastric Inhibitory Polypeptide Dipeptidyl Peptidase Islet Amyloid Polypeptide Growth Hormone Release Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Augustyns, K., Bal, G., Thonus, G., Belyaev, A., Zhang, X.M., Bollaert, W., Lambeir, A.M., Durinx, C., Goossens, F., and Haemers, A., 1999, The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors. Curr. Med.. Chem. 6: 307–317.Google Scholar
  2. Baggiolini, M., Denwald, B., and Moser, B., 1997, Human Chemokines: an update. Ann. Rev. Immunol. 15: 675–705.CrossRefGoogle Scholar
  3. Barrett, A., Rawlings, N., and Woesner, J., 1998, Handbook of Proteolytic enzymesGoogle Scholar
  4. Bell, G.I., 1986, The glucagon superfamily: precursor structure and gene organization. Peptides 7: 27–36.CrossRefPubMedGoogle Scholar
  5. Bongers, J., Lambros, T., Ahmad, M., and Heimer, E.P., 1992, Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim. Biophys. Acta 1122: 147–153.PubMedGoogle Scholar
  6. Bouras, M., Huneau, J.F., and Tome, D., 1996, The inhibition of intestinal dipeptidylaminopeptidase-IV promotes the absorption of enterostatin and des-arginine-enterostatin across rat jejunum in vitro. Life Sci. 59: 2147–2155.CrossRefPubMedGoogle Scholar
  7. Bouras, M., Huneau, J.F., Luengo, C., Erlanson-Albertsson, C., and Tomé, D., 1995, Metabolism of enterostatin in rat intestine, brainmembranes, and serum: Differential involvement of proline-specific peptidases. Peptides 16: 399–405.CrossRefPubMedGoogle Scholar
  8. Bowyer, R.C., Jehanli, A.M.T., Patel, G., Hermon-Taylor, J., 1991, Development of enzyme-linked immunosorbent assay for free human pro-colipaseactivation peptide (APGPR). Clin. Chim. Acta 200: 137–152.CrossRefPubMedGoogle Scholar
  9. Conlon, J.M., and Sheehan, L., 1983, Conversion of substance P to C-terminal fragments in human plasma. Regulatory peptides 7: 335–345.CrossRefPubMedGoogle Scholar
  10. Coy, D.H., Murphy, W.A., Lance, V.A., and Heiman, M.L., 1987, Differential effects of N-terminal modifications on the biological potencies of growth hormone releasing factor analogues with varying chain lengths. J. Med. Chem. 30: 219–222.CrossRefPubMedGoogle Scholar
  11. Coy, D.H., Murphy, W.A., Sueiras-Diaz, J., Coy, E.J., and Lance, V.A., 1985, Structure-activity on the N-terminal region of growth hormone releasing factor. J. Med. Chem. 28: 181–185.CrossRefPubMedGoogle Scholar
  12. Crump, M., Rajarathnam, K., Kim, K-S, Dark-Lewis, I., and Sykes, B., 1998, Solution structure of eotaxin, a chemokine that selectively recruits eosinophils in allergic inflammation. J. Biol. Chem. 273: 22471–22479.PubMedGoogle Scholar
  13. De Meester, I., Korom, S., Van Damme, J., and Scharpé, S., 1999, CD26, let it cut or cut it down. Immunol. Today 20: 367–375.PubMedGoogle Scholar
  14. Deacon, C.F., Holst, J.J., and Carr, R.D., 1999, Glucagon-like peptide-1: A basis for new approaches to the management of diabetes. Drugs Today 35: 159–170.Google Scholar
  15. Dezan, C., Daniel, C., Hirn, J., Sarda, L., and Bellon, B., 1994, Monoclonal antibodies to human pancreatic procolipase: Production and characterization by competitive binding studies. Hybridoma 13: 509–517.PubMedGoogle Scholar
  16. Drucker, D.J., 1998, Glucagon-like peptides. Diabetes 47: 159–169.PubMedGoogle Scholar
  17. Drucker, D.J., Shi, Q., Crivici, A., Sumner-Smith, M., Tavares, W., Hill, M., DeForest, L., Cooper, S., and Brubaker, P.L., 1997, Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat. Biotechnol. 15: 673–677.CrossRefPubMedGoogle Scholar
  18. Dumont, Y., Jacques, D., Bouchard, P., and Quirion, R., 1998, Species differences in the expression and distribution of the neuropeptide Y Yl, Y2, Y4 and Y5 receptors in rodents, guinea pig and primate brains. J. Comp. Neurol. 402: 372–384CrossRefPubMedGoogle Scholar
  19. Erlanson-Albertsson, C., and York, D., 1997, Enterostatin — A peptide regulating fat intake. Obes. Res. 5: 360–372.PubMedGoogle Scholar
  20. Frohman, L.A., Downs, T.R., Williams, T.C., Heimer, E.P., Pan Y.C., and Felix, A.M., 1986, Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2-terminus. J. Clin. Invest. 78: 906–913.PubMedGoogle Scholar
  21. Fulőp, V., Bőcskei, Z., and Polgàr, 1998, Prolyl oligopeptidase: An unusual β-propeller domain regulates proteolysis. Cell 94: 161–170.PubMedGoogle Scholar
  22. Goossens, F., De Meester, I., Vanhoof, G., Hendriks, D., Vriend, G., and Scharpé, S., 1995, The purification, characterization and analysis of primary and secondary-structure of prolyl oligopeptidase from human lymphocytes. Evidence that the enzyme belongs to the α/β hydrolase fold family. Eur. J. Biochem.233: 432–441.Google Scholar
  23. Hartrodt, B., Neubert, K., Fischer, G., Demuth, U., Yoshimoto, T., and Barth, A., 1982, Degradation of β casomorphin-5 by PSE and PPCE. Comparative studies of the β casomorphin-5 cleavage by DPPIV. Pharmazie 37: 72–73.PubMedGoogle Scholar
  24. Heymann, E., and Mentlein, R., 1978, Liver dipeptidylaminopeptidase IV hydrolyzes substance P. FEBS Lett 91: 360–364.CrossRefPubMedGoogle Scholar
  25. Heymann, E., Mentlèin, R., Nausch, I., Erlanson-Albertsson, C., Yoshimoto, T. and Feller, A.C., 1986, Processing of pro-colipase and trypsinogen by pancreatic dipeptidyl peptidase IV. Biomed. Biochim. Acta 45: 575–584.PubMedGoogle Scholar
  26. Hoffmann, T., Faust, J., Neubert, K., and Ansorge, S., 1993, Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences. FEBS Lett. 336: 61–64.CrossRefPubMedGoogle Scholar
  27. Holst, J.J., and Deacon, C.F., 1998, Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47: 1663–1670.PubMedGoogle Scholar
  28. Hu, L., Balse, P., and Doughty, M.B., 1994, Neuropeptide Y N-terminal deletion fragments: Correlation between solution structure and receptor binding activity at Yl receptors in rat brain cortex. J. Med. Chem. 14: 3622–2629.Google Scholar
  29. Huneau, J.F., Erlanson-Albertsson, C., Beauvallet, C., and Tomé, D., 1994, The in vitro intestinal absorption of enterostatin is limited by brush-border membrane peptidases. Regul. Pept. 54: 495–503.CrossRefPubMedGoogle Scholar
  30. Inuis, A., 1999, Neuropeptide Y feeding receptors: Are multiple subtypes involved? TIPS 20: 43–46.Google Scholar
  31. Jarpe, M.B., Knall, C., Mitchell, F.M., Buhl, A.M., Duzic, E., and Johnson, G.L., 1998, [D-Argl, D-Phe5, Trp7,9-Leu11]substance P acts as a biased agonist toward neuropeptide and chemokine receptors. J. Biol. Chem. 273: 3097–3104.CrossRefPubMedGoogle Scholar
  32. Jonas, V, Lin, C.R., Kawashima E., Semon, D., Swanson, L., Mermod, J., Evans, R., and Rosenfeld M., 1985, Alternative RNA processingevents in human calcitonin/calcitonin gene-related peptide gene expression. Proc. Natl. Acad. Sci USA 82: 1994–1998.PubMedGoogle Scholar
  33. Kah, S.E., Andrikopoulos, S., and Verchere, C.B., 1999, Islet amyloid: A long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48: 241–253.Google Scholar
  34. Kähne, T., Lendeckel, U., Wrenger, S., Neubert, K., Ansorge, S., Reinhold, D., 1999, Dipeptidyl peptidase IV: A cell surface peptidase involved in regulating T cell growth. Int. J. Mol. Med. 4: 3–15.PubMedGoogle Scholar
  35. Karzai, W., Oberhoffer, A., Meier-Hellmann, A., Reinhart, K., 1997, Procalcitonin — A new indicator of the systemic response to severe infections. Infect. 25: 329–334.Google Scholar
  36. Leiter, A.B., Toder, A., Wolfe, H.J., Taylor, I.L., Cooperman, S., Mandel, G., and Goodman, R.H., 1987, Peptide YY: Structure of the precursor and expression in exocrine pancreas. J. Biol. Chem. 262: 12894–12988.Google Scholar
  37. Levite, M., 1998, Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype. Proc. Natl. Acad. Sci. 95: 12544–12549.CrossRefPubMedGoogle Scholar
  38. Lin, L., Okada, S., York, D.A., and Bray, G.A., 1994, Structural requirements for the biological activity of enterostatin. Peptides 15: 849–854.CrossRefPubMedGoogle Scholar
  39. Luster, A., 1998, Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338: 436–445.CrossRefPubMedGoogle Scholar
  40. Martin, R.A., Cleary, D.L., Guido, D.M., Zurcher-Neely, H.A., and Kubiak, T.M., 1993, Dipeptidyl peptidase IV (DPP-IV) from pig kidney cleaves analogs of bovine growth hormone-releasing factor (bGRF) modified at position 2 with Ser, Thr or Val. Extended DPP-IV substrate specificity? Biochim. Biophys. Acta 1164: 252–260.PubMedGoogle Scholar
  41. Medeiros, M.S., and Turner, A.J., 1994, Post-secretory processing of regulatory peptides: The pancreatic polypeptide family as a model example. Biochim. 76: 283–287.Google Scholar
  42. Mentlein, R., and Heymann, E., 1982, Dipeptidyl peptidase IV inhibits the polymerization of fibrin monomers. Arch. Biochem. Biophys. 217: 748–750.CrossRefPubMedGoogle Scholar
  43. Mentlein, R., Dahms, P., Grandt, D., and Krüger, R., 1993, Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul. Pept. 49: 133–144.CrossRefPubMedGoogle Scholar
  44. Mentlein, R., Gallwitz, B., and Schmidt, E., 1993, Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-l(7-36)amide, peptide histidine methionine and is reponsible for their degradation in human serum. Eur. J. Biochem. 214: 829–855.CrossRefPubMedGoogle Scholar
  45. Michel, M.C., Beck-Sickinger, A., Cox, H., Doods, H.N., Herzog, H., Larhammar, D., Quirion, R., Schwartz, T., Westfall, T., 1998, XVI.International union of pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 50: 143–150.PubMedGoogle Scholar
  46. Morgan, D.G., Kulkarni, R.N., Hurley, J.D., Wang, Z.L., Wang, R.M., Ghatei, M.A., Karlsen, A.E., Bloom, S.R., and Smith, D.M., 1998, Inhibition of glucose stimulated insulin secretion by neuropeptide Y is mediated via the Y1 receptor and inhibition of adenylyl cyclase in RIN 5AH rat insulinoma cells. Diabetologia 41: 1482–1491.CrossRefPubMedGoogle Scholar
  47. Morimoto, C., and Schlossman, S.F., 1998, The structure and function of CD26 in the T-cell immune response. Immunological Rev. 161: 55–70.Google Scholar
  48. Nilsson, C., Westman, A., Blennow, K, and Ekman, R., 1998, Processing of neuropeptide Y and somatostatin in human cerebrospinal fluid as monitored by radioimmunoassay and mass spectrometry. Peptides 19: 1137–1146.PubMedGoogle Scholar
  49. O’Harte, F.P., Mooney, M.H., Flatt, P.R., 1999, NH2—Terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity. Diabetes 48: 758–765.PubMedGoogle Scholar
  50. Ohtsuki, T., Hosono, O., Kobayashi, H., Munakata, Y., Souta, A., Shioda, T., and Morimoto, C., 1998, stromal cell-derived factor 1α by CD26/dipeptidyl peptidase IV. FEBS Lett. 431: 236–240.CrossRefPubMedGoogle Scholar
  51. Okada, S., York, D.A., Bray, G.A., and Erlanson-Albertsson, C., 1991, Enterostatin (Val-Pro-Asp-Pro-Arg), the activation peptide of procolipase, selectivity reduces fat intake. Physiol. Behav. 49: 1185–1189.CrossRefPubMedGoogle Scholar
  52. Ookuma, M. and York, D.A., 1998, Inhibition of insulin release by enterostatin. Int. J. Obes. Relat.. Metab. Disord. 22: 800–805.CrossRefPubMedGoogle Scholar
  53. Oravecz, T., Pall, M., Roderiquez, G., Gorrell, M.D., Ditto, M., Nguyen, N., Boykins, R., Unsworth, E., and Norcross, M.A., 1997, Regulation of the receptor specificity and function of the chemokine RANTES (Regulated on activatin, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J. Exp. Med. 186: 1865–1872.CrossRefPubMedGoogle Scholar
  54. Prasad, C., Immamura, M., Debata, C., Svec, F., Sumar, N., Hermon-Taylor, J., 1999, Hyperenterostatinemia in premenopausal obese women. J. Clin. Endocrinol. Metabol.84: 937–941.Google Scholar
  55. Proost, P., De Meester, I., Schols, D., Struyf, S., Lambeir, A.M., Wuyts, A., Opdenakker, G., DeClercq, E., Scharpe, S.,and VanDamme, J., 1998, Amino-terminaltruncation of chemokines by CD26/dipeptidyl-peptidase IV. J. Biol. Chem. 273: 7222–7227.CrossRefPubMedGoogle Scholar
  56. Proost, P., Struyf, S., Schols, D., Durinx, C., Wuyts, A., Lenaerts, J.P., De Clercq, E., De Meester, I., and Van Damme, J., 1998, Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-α. FEBS Lett. 432: 73–76.CrossRefPubMedGoogle Scholar
  57. Proost, P., Struyf, S., Schols, D., Opdenakker, G., Sozzani, S., Allavena, P., Mantovani, A., Augustyns, K., Bal, G., Haemers, A., Lambeir, A.M., Scharpé, S, Van Damme, J., and De Meester, I., 1999, Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J. Biol. Chem. 274: 3988–3993.CrossRefPubMedGoogle Scholar
  58. Riemann, D., Kehlen, A. and Langner, J. 1999 CD13 — not just a marker in leukemia typing. Immunol. Today 20, 83–88.CrossRefPubMedGoogle Scholar
  59. Ritzel, U., Leonhardt, U., Ottleben, M., Ruhmann, A., Eckart, K., Spiess, J., and Ramadori, G., 1998, A synthetic glucagon-like peptide-1 analog with improved plasma stability. J. Endocrinol. 159: 93–102.CrossRefPubMedGoogle Scholar
  60. Rocca, A.S., and Brubaker, P.L., 1999, Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 140: 1687–1694.CrossRefPubMedGoogle Scholar
  61. Sanket, T., Bell, G.I., Sample, C., Rubenstein, A.H., and Steiner, D.F., 1988, An islet amyloid peptide is derived from an 89-amino acid precursor by proteolyltic processing. J. Biol. Chem. 263: 17243–17246.Google Scholar
  62. Sato, K., Hotta, M., Kageyama, J., Chiang, T.C., Hu, H.Y., Dong, M.H., and Long, N., 1987, Synthesis and in vitro bioactivity of human growth hormone-releasing factoranalogs substituted with a single D-amino acid. Biochem. Biophys. Res. Commun. 16: 531–517.Google Scholar
  63. Schols, D., Proost, P., Struyf, S., Wuyts, A., De Meester, I., Scharpé, S., Van Damme, J., and De Clercq, E., 1998, CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity. Antivir. Res. 39: 175–187.CrossRefPubMedGoogle Scholar
  64. Shane, R., Wilk, S., Bodnar, R.J., 1999, Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV. Brain Res. 815: 278–286.CrossRefPubMedGoogle Scholar
  65. Siegel, E.G., Gallwitz, B., Scharf, G., Mentlein, R., Morys-Wortmann, C., Főlsch, U.R., Schrezenmeir, J., Drescher, K., and Schmidt, W.E., 1999, Biological activityof GLP-1 analogues with N-terminal modifications. Regul. Pept. 79: 93–102.CrossRefPubMedGoogle Scholar
  66. Struyf, S., Proost, P., Schols, D., De Clercq, E., Opdenakker, G., Lenaerts, J.P., Detheux, M., Parmentier, M., De Meester, I., Scharpé, S., and Van Damme, J., 1999, CD26/Dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J. Immunol. 162: 4903–4909.PubMedGoogle Scholar
  67. Thomson, A., Schoeller, C., Keelan, M., et al, 1993, Lipid absorption: Passing through the unstirred layers, brush border membrane, and beyond. Can. J. Physiol. Pharmacol. 71: 531–555.PubMedGoogle Scholar
  68. Van Damme, J., Struyf, S., Wuyts, A., Van Coillie, E., Menten, P., Schols, D., Sozzani, S., D Meester, I., and Proost, P., 1999, The role of CD26/DPP IV in chemokine processing. Chem. Immunol. 72: 42–56.PubMedGoogle Scholar
  69. van Hulst, K.L., Oosterwijk, C., Born, W., Vroom, Th.M., Nieuwenhuis, M.G., Blankenstein., M.A., Lips, C.J.M., Fischer, J.A, and Hőppener, J. W.M., 1999, Islet amyloid polypeptide/amylin messenger RNA and protein expression in human insulinomas in relation to amyloid formation. Eur. J. Endocrinol. 140: 69–78.PubMedGoogle Scholar
  70. van Tilbeurgh, H., Sarda, L., Verger, R., and Cambillau, C., 1992, Structure of the pancreatic lipase-procolipase complex. Nature 359: 159–162.PubMedGoogle Scholar
  71. von Bonin, A., Hühn J. and Fleisher, B. 1998 Dipeptidyl peptidase IV/CD26 alternative T-cells: analysis of an alternative activation pathway. Immunological Rev. 161: 43–53.Google Scholar
  72. Westermark, P., Engstrom, U., Westermark, G.T., Kohnson, K.H., Permerth, J., Betsholtz, C. 1989 Islet amyloid polypeptide (IAPP) and pro-IAPP immunoreactivity in human islets of Langerhans. Diab. Res. Clin. Pract. 18: 219–226.Google Scholar
  73. Winkler, H., and Fischer-Colbrie, 1992, The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 49: 497–528.CrossRefPubMedGoogle Scholar
  74. Wuyts, A., Govaerts, C., Struyf, S., Lenaerts, J.P, Put, W., Conings, R., Proost, P., and Van Damme, J., 1999 Isolation of the CXC chemokines ENA-78, GRO alpha and GRO gamma from tumor cells and leukocytes reveals NH2-terminal heterogeneity. Functional comparison of different natural isoforms. Eur. J. Biochem. 260: 421–429.CrossRefPubMedGoogle Scholar
  75. Yaron, A., and Naider, F., 1993, Proline-dependent structural and biological properties of peptides and proteins. Crit. Rev. Biochem. Mol. Biol. 28: 31–81.PubMedGoogle Scholar
  76. Zhang, X.Y., De Meester, I., Lambeir, A.M., Dillen, L., Van Dongen, W., Esmans, E.L., Haemers, A., Scharpé, S., Claeys, M., 1999, Study of the enzymatic degradation of vasostatin I and II and their precursor chromogranin A by dipeptidyl peptidase IV using high-performance liquid chromatography/electrospray mass spectrometry. J. Mass Spectrom. 34: 255–263.PubMedGoogle Scholar
  77. Zukowska-Grojec, Z., 1997, Neuropeptide Y: Implications in vascular remodeling and novel therapeutics. DN & P 10: 587–595.Google Scholar
  78. Zukowska-Grojec, Z., Karwatowska-Prokopczuk, E., Rose, W., Rone, J., Movafagh, S., Ji, H., Yeh, Y., Chen, W.T., Kleinman, H.K., Grouzmann, E., and Grant, D.S., 1998, Neuropeptide Y: A novel angiogenic factor from the sympathetic nerves and endothelium. Circ. Res. 83: 187–195.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Ingrid De Meester
    • 1
  • Christine Durinx
    • 1
  • Gunther Bal
    • 2
  • Paul Proost
    • 3
  • Sofie Struyf
    • 3
  • Filip Goossens
    • 1
  • Koen Augustyns
    • 2
  • Simon Scharpé
    • 1
  1. 1.Laboratory of Clinical BiochemistryUniversity of AntwerpWilrijkBelgium
  2. 2.Laboratory of Pharmaceutical ChemistryUniversity of AntwerpWilrijkBelgium
  3. 3.Laboratory of MolecularImmunology Rega Institute for Medical ResearchUniversity of LeuvenLeuvenBelgium

Personalised recommendations